Merck Acquires Bio-Techne in $11.3 Billion M&A Deal

Global mergers and acquisitions activity received another major boost this week as German science and technology giant Merck KGaA announced plans to acquire Bio-Techne in an all-cash transaction valued at approximately $11.3 billion. The deal is expected to strengthen Merck's position in the rapidly evolving life sciences market and reflects the growing appetite for strategic acquisitions across the healthcare and biotechnology sectors.

Under the agreement, Merck will pay $73 per share for Bio-Techne, representing a significant premium over the company's recent trading levels. The acquisition marks one of the largest life sciences transactions announced this year and underscores the importance of specialized biotechnology platforms in supporting pharmaceutical innovation.

Bio-Techne has established itself as a leading provider of proteins, antibodies, diagnostic technologies, and genomic research tools used by pharmaceutical companies, research institutions, and biotechnology firms worldwide. Its solutions play a critical role in drug discovery, cell and gene therapy development, and precision medicine initiatives.

The acquisition is expected to enhance Merck's Life Science division by expanding its portfolio of research and laboratory solutions. Industry observers believe the combined capabilities could help accelerate innovation in biopharmaceutical manufacturing and advanced healthcare research.

"Bio-Techne's technologies complement our long-term strategy of supporting scientific discovery and next-generation healthcare solutions," Merck said while announcing the transaction. The company added that the acquisition aligns with its goal of delivering integrated solutions across the research and development value chain.

The transaction is also significant because it represents one of the first major strategic moves under Merck's new Chief Executive Officer, Kai Beckmann. Analysts view the deal as a signal that large healthcare and life sciences companies remain willing to pursue sizable acquisitions despite ongoing economic uncertainty and regulatory scrutiny.

Across the global M&A landscape, healthcare continues to be among the most active sectors. Companies are increasingly seeking acquisitions to gain access to specialized technologies, strengthen product pipelines, and accelerate growth in high-value markets. The rise of AI-driven drug discovery, personalized medicine, and advanced diagnostics has further increased the strategic value of biotechnology firms with differentiated capabilities.

Industry experts expect life sciences dealmaking to remain robust through the second half of 2026 as organizations pursue scale, innovation, and operational efficiencies. Transactions such as the Merck–Bio-Techne deal demonstrate how companies are using acquisitions not only to expand market presence but also to secure critical technologies that can drive future growth.

The acquisition remains subject to shareholder and regulatory approvals and is expected to close in late 2026 or early 2027. Once completed, the combined organization is expected to have a stronger global footprint across research tools, diagnostics, and biopharmaceutical services, positioning it to capitalize on growing demand for advanced healthcare solutions worldwide.